Icahn Boosts Stake in Biogen Idec (BIIB) to 6% Following TYSABRI Sell-Off
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Down)Join SI Premium – FREE
In a 13D filing on Biogen Idec (Nasdaq: BIIB), Carl Icahn disclosed he raised his stake in the company to 6.03% (17,511,304 shares). This is up from the 9,948,723 share stake held at the quarter ended 3/31/08.
Icahn noted that his representatives have had, and from time to time may seek to continue to have, discussions with representatives of Biogen Idec to discuss general business issues relating to the Issuer as well as their concerns relating to shareholder value.
Icahn disclosed he paid $916,501,219 for the position, or about $52 per share. Shares of Biogen are currently at $50.76.
Shares of Biogen Idec sank 28% on 8/1 after disclosing two additional TYSABRI-relate PML cases. The filing showed, Icahn accumulated large sums of stock after that drop.
Icahn noted that his representatives have had, and from time to time may seek to continue to have, discussions with representatives of Biogen Idec to discuss general business issues relating to the Issuer as well as their concerns relating to shareholder value.
Icahn disclosed he paid $916,501,219 for the position, or about $52 per share. Shares of Biogen are currently at $50.76.
Shares of Biogen Idec sank 28% on 8/1 after disclosing two additional TYSABRI-relate PML cases. The filing showed, Icahn accumulated large sums of stock after that drop.
You May Also Be Interested In
- Biogen (BIIB) April weekly option implied volatility into quarter results
- Marriott Vacations Worldwide (VAC) ticks higher on new activist investor
- Biogen (BIIB) PT Lowered to $270 at Oppenheimer
Create E-mail Alert Related Categories
13Ds, Insiders' BlogRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
